ArticleJCO precision oncology2024

Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression.

Ben L Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.